Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients.

Lieberman J, Skolnik PR, Parkerson GR 3rd, Fabry JA, Landry B, Bethel J, Kagan J.

Blood. 1997 Sep 15;90(6):2196-206.

PMID:
9310470
2.

Recognition of a small number of diverse epitopes dominates the cytotoxic T lymphocytes response to HIV type 1 in an infected individual.

Lieberman J, Fabry JA, Fong DM, Parkerson GR 3rd.

AIDS Res Hum Retroviruses. 1997 Mar 20;13(5):383-92.

PMID:
9075479
3.

EBV-specific cytotoxic T lymphocytes protect against human EBV-associated lymphoma in scid mice.

Buchsbaum RJ, Fabry JA, Lieberman J.

Immunol Lett. 1996 Sep;52(2-3):145-52.

PMID:
8905410
4.

Three regions of HIV-1 gp160 contain clusters of immunodominant CTL epitopes.

Shankar P, Fabry JA, Fong DM, Lieberman J.

Immunol Lett. 1996 Aug;52(1):23-30.

PMID:
8877415
5.

A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees.

Perales MA, Schwartz DH, Fabry JA, Lieberman J.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Sep 1;10(1):27-35.

PMID:
7648281
6.

CD43 diminishes susceptibility to T lymphocyte-mediated cytolysis.

McFarland TA, Ardman B, Manjunath N, Fabry JA, Lieberman J.

J Immunol. 1995 Feb 1;154(3):1097-104.

PMID:
7822786
7.

Ex vivo expansion of HIV type 1-specific cytolytic T cells from HIV type 1-seropositive subjects.

Lieberman J, Fabry JA, Shankar P, Beckett L, Skolnik PR.

AIDS Res Hum Retroviruses. 1995 Feb;11(2):257-71.

PMID:
7742040
8.

Cytotoxic T lymphocytes from HIV-1 seropositive individuals recognize immunodominant epitopes in Gp160 and reverse transcriptase.

Lieberman J, Fabry JA, Kuo MC, Earl P, Moss B, Skolnik PR.

J Immunol. 1992 May 1;148(9):2738-47.

PMID:
1374097

Supplemental Content

Loading ...
Support Center